Two Chinese Drug Makers Said To Plan IPOs Elsewhere
This article was originally published in PharmAsia News
Executive Summary
A Hong Kong newspaper reports two major Chinese drug makers plan to issue initial public offerings away from mainland China, one in Hong Kong, the other in New York. The South China Morning Post said the China National Pharmaceutical Group plans to issue an initial public offering later this year in Hong Kong to raise $750 million, while CITIC Pharmaceutical considers a $200 million offering in New York next year. China National, known as Sinopharm, would spin off its subsidiaries for distribution and manufacturing, both located in mainland China, the report said. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.